Assessment and Management of Ascites in Patients with Prior Alcoholic Cirrhosis and Normal Liver Enzymes

1. Diagnostic Evaluation

Ascites indicates portal hypertension regardless of transaminase levels; a serum‑ascites albumin gradient (SAAG) ≥ 1.1 g/dL confirms portal hypertension with ≈ 97 % accuracy, supporting a diagnosis of cirrhosis. – American Association for the Study of Liver Diseases (AASLD) 6
Diagnostic paracentesis should be performed immediately to obtain SAAG, total protein, cell count, differential, and cultures. – AASLD 1
Spontaneous bacterial peritonitis (SBP) is ruled out when the ascitic fluid neutrophil count is ≤ 250 cells/mm³; a count > 250 cells/mm³ mandates treatment for SBP. – AASLD 5
Approximately 15 % of ascites cases are due to non‑cirrhotic etiologies (e.g., malignancy, heart failure, tuberculosis) and 5 % have mixed causes; these should be considered when SAAG is low or clinical picture is atypical. – AASLD 7
Additional non‑invasive markers that aid cirrhosis detection include low platelet count, hypoalbuminemia, and imaging evidence of hepatic nodularity or splenomegaly. – Korean Association for the Study of the Liver (KASL) 8

Patients with Child‑Pugh class C alcoholic cirrhosis who achieve abstinence have an estimated 75 % three‑year survival, whereas continued drinking is associated with essentially 0 % three‑year survival. – AASLD 3
Anemia (e.g., hemoglobin ≈ 8.6 g/dL) in this setting suggests decompensated disease, potentially from variceal bleeding, hypersplenism, or chronic disease, and correlates with poorer outcomes. – KASL 4

Abstinence yields rapid improvement in the reversible (inflammatory) component of alcoholic liver disease over months, but established fibrosis and portal hypertension are largely irreversible. – AASLD 2
While abstinence can lead to resolution or better responsiveness of ascites to medical therapy in some patients, a subset will continue to experience decompensation despite years of sobriety. – AASLD 1

First‑line ascites therapy consists of sodium restriction (≈ 2 g/day) combined with oral diuretics—spironolactone 100 mg plus furosemide 40 mg daily, titrated every 3–5 days as needed. – AASLD 9
All patients with cirrhosis and ascites should be evaluated for liver transplantation eligibility. – AASLD 10
Continued abstinence must be reinforced; any relapse accelerates disease progression and increases mortality. – AASLD 2

Normal transaminases (AST, ALT, GGT) do not exclude cirrhosis; they reflect hepatocellular injury rather than synthetic function or portal hypertension. – AASLD 1

All facts are derived from peer‑reviewed sources and reflect current AASLD and KASL recommendations.